Home > Boards > US Listed > Cannabis >

Rafarma Pharmaceuticals Inc. (RAFA)

Add RAFA Price Alert      Hide Sticky   Hide Intro
Moderator: IB_, Investorr, ScottRVA1
Search This Board: 
Last Post: 11/26/2021 11:43:40 AM - Followers: 100 - Board type: Free - Posts Today: 0

Official Website:

Current Share Structure:

Leadership Page:

Rafarma is actively involved in the process of establishing contractual partnerships with approximately 200 companies in various countries, to be finalized by the summer of 2022. 

>These include the USA, the EU and the ASEAN countries, China, Japan, Singapore, South Africa and Russia. Contractual partnerships have already been finalized with several companies in China, Uzbekistan, Czech Republic, Singapore, Malaysia and Russia.

Current R & D Projects:

Location: Haifa, Israel, 2021, Joint Venture with the Matam Technopark in Haifa, Israel
-Exosome research for pharmaceutical production and use, as well as joint research toward an artificially-created, modified bacterium to form a therapeutic platform for new drug designs.

Location: Uzbekistan, 2021, Joint Venture with Health Department of Uzbekistan
-Projected costs are currently at $82,000,000
-Construction started in Early 2021.
See the construction here:

Location: Moscow, 2021, Self-funded
Construction of site for contact production of adenovirus vector

Location: Batan - Indonesia, 2021-2023, Self-funded + bond loan
Construction of a plant and laboratories in Indonesia

Location: Krasnoyarsk-Russia, Czech Republic, 2021-25, Self-funded
Construction of production sites for sterile preparations

Location: Yver Region - Russia, 2021, Self-funded + bank loans
Construction of production sites for non-sterile drugs

Location: Dubna - Moscow Region, 2020-21, Self-funded
Reconstruction of an enterprise for radioopharmaceuticals

Location: Krasnoyarsk-Russia, 2020-21, Self-funded
Reconstruction of the R & D lab

Location: Istanbul-Turkey, 2021-25
Istanbul nuclear medicine center project

Location: Pereslavi-Russia, 2021-23
Nuclear medicine center near Moscow

Location: New York - USA, 2021-22
Construction of a laboratory on artificial immunity technologies in the suburbs of New York

Location: Kumertau-Bashkiria, Pereslavi-Yaroslavl region 2021-24
Reconstruction/construction of biotechnological production centers in the Czech Republic, Yaroslavi region, Bashkiria

Merged has closed!:

Reverse Merger of Biocogency into Rafarma Pharmaceuticals Creates Substantial Unrealized Shareholder Value:

Biocogency with $73 million 2019 sales recently acquired majority control and merged all operations into Rafarma Pharmaceuticals

There was no dilution to Rafarma shareholders and all operations and assets of both companies will be combined and reported under the ticker RAFA

The merger increased Rafarma Pharmaceuticals 2019 revenues from $11.4 million to $84 million

Elite accounting firm, L. J. Soldinger is retained to perform audited financials

Wealthy international industrialist, Ilya Shpurov is now Chairman of the Board of Rafarma Pharmaceuticals

  • With 2019 combined sales of $84 million, current market cap of $131 million, extraordinary strong growth, and share price of $1.69, market comps point to share price valuation several multiples higher than current price

Many OTC stocks are easily overlooked because they don't get the coverage of peers traded on national exchanges and consequently very few investors have the opportunity to know about them. A perfect example is the recent closing of a reverse merger increasing sales by over 700% and adding sizable international operations of private Biocogency into Rafarma Pharmaceuticals (OTC: RAFA) where the RAFA share price has not yet reflected the new added value.


On October 19, 2020, the merger of Biocogency into Rafarma was announced and went unnoticed. Although important metrics to determine share valuations have soared as a result of the merger, the share price has not yet caught up reflecting the new increased valuations simply because nobody knows about it yet. As word is likely to spread soon, the share price is expected to begin climbing to more fair and reasonable market valuations that could exceed expectations.


About Rafarma Pharmaceuticals

Rafarma Pharmaceuticals, Inc., a multi-product pharmaceutical company, produces and sells cannabis health-related products and specialty pharmaceuticals. The company formerly known as Johnston Acquisition Corp. changed its name to Rafarma Pharmaceuticals, Inc. and is based in Sandy, Utah with a manufacturing and distribution facility in Russia.

About Biocogency

Biocogency owns PJSC "Krasfarma", the largest Russian chemical and pharmaceutical production company with more than 50 years of experience in the production of drugs that meet all national and international quality standards.

The Company helps meet the growing needs of health care for high-quality, effective and safe generic pharmaceuticals as well as development and production of innovative pharmaceutical products. Production systems with a strong emphasis on safety are carried out through a coordinated interaction of their quality control department, commercial department, logistics service, and scientific information department and pharmacovigilance services.

A rich history is not the most important thing in the modern pharmaceutical industry. To keep the quality of products on a permanently high level, a program of production modernization is being realized: investments in the company include new industrial lines, engineering systems and control systems, as well as new pharmaceutical products.

Safe and effective generic medicines of PJSC "Kraspharma", which are not inferior in clinical efficacy to the original, but sold at affordable prices, have won the trust of both doctors and patients.

Today PJSC "Kraspharma" is the Eastern Europe and Russia undisputed leader in the production of:

  • Antibiotics;
    tuberculosis drugs in injectable forms;
    Blood substitutes;
    infusion solutions;
    Preparations of other pharmacological groups.

Most of the drugs produced are included in Vital and Essential Drugs List (VED) approved by the Government of the Russian Federation.

The products of PJSC "Kraspharma" are sold in Russia, Eastern Europe, Central Asia and in the countries of the Asia-Pacific region.

What Biocogency Adds to Rafarma


This transformative merger starts by restating Rafarma 2019 sales from $11.4 million to $84 million and delivers impressive growth rates of close to 50%.


The Biocogency group includes Russia-based drug companies Bebig and PJSC Kraspharma and industrial firm Slavich. Bebig is focused on developing therapies and diagnostics for cancer care in the Russian markets, including supplying microsources for the treatment of prostate cancer using low-dose brachytherapy. Kraspharma, Russia's largest chemical and pharmaceutical production company (and crown jewel of the merger), and Slavich, a manufacturer of a variety of products including packaging goods, materials for microelectronics and photo materials, are both steeped in corporate history going back half a century or more in Russia.


Biocogency also brings leadership committed to growing value as measured by the fact the deal was structured to be non-dilutive to existing RAFA shareholders. To that point, Ilia Shpurov has assumed the position of Chairman of the Board, bringing decades of entrepreneurial – and biotech – success to RAFA.


What's in it for RAFA? An Immediate Spike in Revenue and Profits


The merger with Biocogency is a game changer for RAFA operations and the top and bottom lines. Consider that in 2019, RAFA generated revenue of approximately $11.4 million and gross profit of $3.4 million. In the latest quarter, ended July 31, 2020, Rafarma reported revenue of $5.3 million and gross profit of $3.1 million, according to filings with OTC Markets Group.


Those results are going to get an immediate shot of adrenaline.


During fiscal 2019, the Biocogency group reported unaudited consolidated earnings of $73 million and gross profits of $17 million. As a course of becoming fully reporting and planning to uplist, the financial results are being audited and adjusted to meet GAAP standards.


Using the results from 2019, it is easy to extrapolate pro forma revenue of $84.4 million and gross profit of $20.3 million for the combined company. It is those type of financials that will underpin a move to the Nasdaq or NYSE.


More on how the price to sales ratio stacks up to industry comps are discussed here. Several Pharmaceutical market comps point to Rafarma share prices that are many multiples higher than the current price of $1.69.


When it comes to value, it certainly bears mentioning the investments that Biocogency has put into its pipeline and platforms since 2012, which management pegs at more than $120.0 million. Much of this investment has been directed by Shpurov since he bought the Kraspharma during the outbreak of the global financial collapse in 2008 for the purpose of restoring and expanding production volumes post-recession while establishing a high-tech GMP pharmaceutical manufacturer in Krasnoyarsk.


That was accomplished. Today, Kraspharma is a leading producer of wide swath of generic drugs and pharma products spanning antibiotics, blood substitutes, infusion solutions, tuberculosis and preparations for other pharmacological groups. Sales channels extend throughout Russia, Eastern Europe and the Asia-Pacific region.


Widening the Footprint


The plan is for vertical growth by expanding the existing channels while leveraging RAFA relationships for horizontal growth through entering the lucrative North American markets.


In fairness, Russia alone can be a company maker. A huge net importer of medicine, the Russian government is pushing for national security in the supply chain as outlined in the Pharma 2030 Strategy. With that in mind, Statista forecasts the Russian pharmaceutical industry will grow 147% between 2017 and 2030.


During Q1, the Russian pharma market surged 125% year-over-year to about 320 billion Russian rubles (US$4.2 billion). Generic drugs typically dominate the prescription market, accounting for 64.5% of the category in 2017, meaning Kraspharma is in a strong position.


Given the sheer volume of people, Asia is another tremendous market. The Rx market in China alone is forecast to reach $160 billion by 2022, highlighting the market opportunity. With respect to the Asian drug development market, ResearchAndMarkets estimates 6.54% compound annual growth to reach $62.46 billion by 2026.


Still, the U.S. is the Holy Grail as the biggest pharmaceutical market in the world, weighing in at a whopping $484.4 billion in 2018.



With the reverse merger now closed, the newly created Rafarma Pharmaceuticals that now boasts fast-growing operations well in excess of $100 million for 2019 is decidedly undervalued when compared to industry valuations for similar companies. Management plans for uplisting and higher investor awareness programs are soon in the future which will help bring the Rafarma opportunity to the forefront resulting in substantially higher prices and trading volume.

The current price has not yet appreciated to reflect the newly increased sales and valuations and therefore presents an opportunity to astute investors who act now before the story becomes more commonly known.


The asia hemp market will be huge!

This analyst explains the company well:
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
#5648  Sticky Note New $Rafa Report...Price Target Raised to $16. Nice! Investorr 07/21/21 11:12:20 AM
#5190  Sticky Note more birdman- honest report from the court snakess 10/26/20 10:09:12 PM
#5744   $RAFA Explosive Growth Launches Kraspharma Into REMEDIUM TOP-5 AskMuncher 11/21/21 02:28:39 PM
#5743   $7 million more cash on hand than last Investorr 11/15/21 11:27:36 PM
#5742   From Stocktwits... Marty Byrd 11/15/21 09:51:19 PM
#5741   *RAFA* Company “Rafarma Pharmaceuticals Inc.” Combined Financial Investorr 11/15/21 07:56:13 PM
#5739   Hopefully RAFA will continue to climb !!!!!!!!!!!!!!!!!!!!! IB_ 11/12/21 11:58:46 PM
#5738   I've been trying to average down since I knick 11/12/21 05:53:05 PM
#5736   Very nice day for those who bought RAFA IB_ 11/11/21 04:12:28 PM
#5735   Well we know 2020 audits are probably done Investorr 11/11/21 12:04:02 PM
#5734   Volume and price jump… only 1 day, but ScottRVA1 11/11/21 12:00:21 PM
#5733   Major exchanges are absolutely interested in a company Investorr 11/11/21 08:42:43 AM
#5732   RAFA is not going on the Nasdaq or IB_ 11/11/21 08:13:55 AM
#5731   They should qualify for both NYSE and Nasdaq Investorr 11/10/21 10:03:34 PM
#5729   Up list to what ????????????????????????? IB_ 11/10/21 08:25:28 PM
#5728   Not really that slow. They had to go Investorr 11/10/21 04:47:30 PM
#5727   I have not been short RAFA for almost IB_ 11/10/21 04:24:22 PM
#5726   Great. Stay short then. 2020 audit could drop Investorr 11/10/21 11:14:45 AM
#5725   Rafarma is a "Coulda, Woulda, Shoulda Stock !!!!!!!!!!!!!!!!!!!!!!! IB_ 11/10/21 11:13:18 AM
#5724   LOL. A company with unlimited money can do Investorr 11/10/21 11:03:01 AM
#5723   So what exchange does Rafarma expect to up IB_ 11/10/21 10:58:55 AM
#5722   Pretty good actually. 2020 audit done and Investorr 11/10/21 10:44:31 AM
#5721   How is Rafarma's up listing coming along on IB_ 11/10/21 10:35:50 AM
#5720   $RAFA Status Update to Shareholders from Rafarma Pharmaceuticals, Inc. AskMuncher 11/10/21 10:17:07 AM
#5718  Restored Rafarma can apply all they want to but IB_ 11/09/21 11:53:41 AM
#5717   Loving the news yesterday…”This enables Rafarma to apply Investorr 11/09/21 10:55:46 AM
#5716  Restored RAFA looking not so good today following the IB_ 11/09/21 10:34:24 AM
#5715   2020 audits done now. 2021 audits to Investorr 11/09/21 05:19:03 AM
#5714  Restored Wrong !! RAFA is not a Fully Audited IB_ 11/08/21 09:57:30 PM
#5712   RAFA is not even a fully reporting company IB_ 11/08/21 06:49:17 PM
#5711   Wrong. There is no dilution to the company Investorr 11/08/21 06:34:53 PM
#5710   $9.5 Million will come at a heavy price IB_ 11/08/21 06:33:40 PM
#5709   Great news today! -Putting $9.5 million into Investorr 11/08/21 02:39:43 PM
#5708   Will RAFA ever break through a dollar again ..................... IB_ 11/08/21 12:59:44 PM
#5707   I did sell RAFA around 1.50 and bought PEACHMAN 11/02/21 09:09:12 AM
#5706   Nice grab! Quarter/year-end tax prep flush made for ScottRVA1 10/29/21 09:03:23 PM
#5705   I added 25k shares today on the dip. Investorr 10/29/21 05:03:39 PM
#5703  Restored Now RAFA will be using the COVID excuse Marty Byrd 10/29/21 04:37:43 PM
#5702   https://www.npr.org/2021/10/28/1049976625/moscow-russia-covid-deaths-lockdown speedo94947 10/29/21 02:39:54 PM
#5690   Yup. As the price and volume is so ScottRVA1 10/23/21 10:35:24 AM
#5689  Restored RAFA looks terrible! Truth Dig It 10/22/21 10:33:22 AM
#5688   I'm hoping and ready for the same.. Jaxlyn 10/15/21 12:10:21 PM
#5687   I definitely agree, but I was very excited ScottRVA1 10/15/21 06:18:46 AM
#5686   I'm feeling it's definitely a bad look for Jaxlyn 10/13/21 12:57:37 PM
#5685  Restored RAFA is DeaD !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! IB_ 10/10/21 02:20:10 AM
#5684   Yep. Audit changes everything. It allows us to Investorr 10/02/21 05:24:39 PM
#5683   Audit in the next 2 weeks… it should ScottRVA1 10/02/21 08:36:42 AM
#5680  Restored RAFA, just another scam ran by The Lying IB_ 08/30/21 02:10:21 PM
#5679   But maybe vodka can help!!!! Marty Byrd 08/22/21 12:06:44 AM
#5678   Platinum based drugs do not appear to be Marty Byrd 08/22/21 12:06:04 AM
#5677   $RAFA Rafarma Enters Negotiations With Leading Global Producer AskMuncher 08/21/21 11:57:07 PM
#5676   Wow. Rafa is becoming a mega-company in front Investorr 08/20/21 06:02:54 AM
Consent Preferences